Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Guggenheim Downgrades Relmada Therapeutics to Neutral

Guggenheim analyst Yatin Suneja downgrades Relmada Therapeutics (NASDAQ:RLMD) from Buy to Neutral.
byBenzinga Newsdesk
October 14, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Guggenheim analyst Yatin Suneja downgrades Relmada Therapeutics (NASDAQ:RLMD) from Buy to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts